Early growth response genes: from structure to function {#sec1}
=======================================================

Early growth response genes are family of transcription factors comprises four members Egr1(Krox-24/NGFI-A), Egr2(Krox-20), Egr3(NGFI-3/Pilot) and Egr4(NGFI-C) which contain three cyc2-His2 zinc fingers binding to the same cognate GC-rich consensus DNA binding motif of 28-30 amino acids, the Egr response element ([Fig. 1](#f0001){ref-type="fig"}) \[[@cit0001], [@cit0002]\]. They are expressed in many different cell types and their expression is rapidly induced in response to mitogens, differentiation, apoptotic signals and tissue injury \[[@cit0003]\].

![Schematic representing structure of four members of the Egr family \[[@cit0001]\]](CEJI-42-30448-g001){#f0001}

Egr1 plays a role in thymocyte development and promotes positive selection of both CD4 and CD8 single positive cells without having a major effect in negative selection, by enhancing expression of anti-apoptosis molecule bcl-2 and Id3 inhibitor \[[@cit0004]\]. Id3 promotes thymocyte maturation in which its expression is up-regulated in response to TCR signaling during positive selection \[[@cit0005], [@cit0006]\]. Egr1 expression is essential for macrophage lineage differentiation \[[@cit0007]\].

Egr2 expression is associated with the onset of myelination in the peripheral nervous system and hindbrain development \[[@cit0002]\]. Egr3 has a vital role in muscle-spindle development \[[@cit0008]\].

Egr4 that was firstly identified in the central nervous system, is mostly expressed at high levels in the forebrain and has critical role in spermatogenesis in terms of male murine fertility \[[@cit0009]\]. It is identified as a novel regulator of posterior hindbrain development \[[@cit0010]\].

Indispensible role of Egr2 and Egr3 in T and B cell development and activation {#sec2}
==============================================================================

Egr2 and Egr3 are expressed in the selected stages of B and T cell development in the thymus and bone marrow respectively \[[@cit0011]\]. They are repressed in immature single positive (ISP) thymocytes and pro-B cells which suggest an indispensible role of Egr molecules for the development of double negative (DN) cells following β selection. Double negative cells are lymphocytes bearing a and β T cell receptor but lacking CD4 and CD8 markers \[[@cit0012]\]. Egr2 expression is withdrawn after β selection for the differentiation of immature single positive (ISP) cells to double positive (DP) cells \[[@cit0011]\]. Double positive cells express both CD4 and CD8 cell surface markers during T cell development \[[@cit0012]\]. T and B cells from Egr2 and 3 knock out showed severe defects in proliferation and IL-2 production after antigenic receptor stimulation *in vitro* \[[@cit0013]\].

Egr2 is vital regulator in a growth-suppressive manner {#sec3}
======================================================

Early studies highlighted the role of Egr genes in cell proliferation \[[@cit0014]\]. Egr2 has been suggested as a mediator of the PTEN growth-suppressive signaling pathway \[[@cit0015]\]. In this process PTEN, a gene located in the cytoplasm acting as a tumor suppressor, induces Egr2 expression and then Egr2 directly transactivates expression of two pro-apoptotic proteins of Bcl-2 family, BNIP3L and BAK, localized at mitochondria and alter the permeability of mitochondrial membranes, releasing cytochrome c and activating caspase 3, 8 and 9 \[[@cit0016]\]. This suggested that exogenous expression of Egr2 can have growth suppressive effects and Egr2 may be an excellent target molecular gene therapy to treat a variety of cancers. A recent study also shows that Egr2 is growth inhibitory when overexpressed in tumor cells and induced CEBPB, transcription factor that contributes to OIS in primary human and mouse fibroblasts that express oncogenic Ras or BRAF \[[@cit0017]\].

In addition, Egr2 attenuates pre-osteoclast proliferation by restraining cell-cycle progression in which Egr2 silencing can result in accelerated proliferation likely due to the increased cFms expression and signalling \[[@cit0018]\].

Constitutive expression of Egr2 in schwann cells reveals a major function of Egr2 in which it suppresses the c-Jun NH2-terminal protein kinase (JNK)-c-Jun pathway, activation of which is required for both proliferation and death. Thus, Egr2 can coordinately control suppression of mitogenic and death responses \[[@cit0019]\]. So, this dual function allows Egr2 to suppress both cell division and death through a single action namely inactivation of the JNK-c-Jun pathway. In contrast, Egr2 knockdown inhibit proliferation and spheroidal growth in vitro and induced regression of Ewing sarcoma xenografts, reduced cell cycle progression through S phase and reduced cell viability \[[@cit0020]\].

Maintenance of Peripheral Tolerance Mechanisms {#sec4}
==============================================

Anergy, apoptosis and the action of regulatory T cells are the mechanisms used by the immune system to maintain tolerance to self-antigens and prevent the development of autoimmunity \[[@cit0021], [@cit0022]\]. Egr2/3 genes are able to induce anergy in both in vitro and in vivo conditions \[[@cit0023]-[@cit0025]\]. Egr2 and Egr3 are negative regulators of T cell activation and inhibit T cell function by blocking the upregulation of NAB2 and Egr1 \[[@cit0025]\]. NAB2 by acting as a coactivator collaborates with Egr1 and promotes IL-2 production \[[@cit0026]\]. Cbl-b was increased in cells overexpressing Egr2 and Egr3, and T cells from Egr3^-/-^ had much less Cbl-b in comparison to controls from wild-type mice, supporting the hypothesis that Egr2 and Egr3 can promote upregulation of inhibitory genes involved in T cell activation \[[@cit0027]\]. Silencing Egr2 gene expression prevents full induction of anergy and increase CD3+CD28- stimulated cells responsiveness to stimulation, resulting in restored proliferation and IL-2 production in anergic cells in which it demonstrate Egr2 role in conferring the anergic state \[[@cit0028]\]. A recent study has identified Ndrg1 as a T cell clonal anergy factor induced by Egr2 that is up-regulated by anergic signaling and maintained at high levels in resting anergic T cells, leading to inhibition of T-cell mediated inflammation \[[@cit0029]\].

Egr transcription factors and the development of inflammation and systemic autoimmune disease {#sec5}
=============================================================================================

Toxic substances released by the activities of virulence factors, allergens, foreign bodies and necrotic cells are stimulants for inflammatory responses and inflammation initiates a physiological response to deregulated homeostasis due to stimulants. This allows the recruitment of non-residential leukocytes to the local sites of infection or tissue injury \[[@cit0030]\]. Inflammation is generally divided by two categories in which it may be acute, leading to the resolution of inflammation or chronic with persistent with presence of inflammatory molecules and cells \[[@cit0031]\]. Egr2 and Egr3 are essential for the control of inflammation and antigen induced proliferation of B and T cells, So analysis of CD2-Egr2^-/-^ and Egr3^-/-^ mice resulted in the reduced activation of SOCS1 and SOCS3 in which led to increased activation of IFN-g and Th17 polarization respectively, suggesting vital role of Egr2 and Egr3 not only in preventing the development of autoimmune disease, but also for limiting immunopathology during productive adaptive immune responses ([Fig. 2](#f0002){ref-type="fig"}) \[[@cit0013], [@cit0032]\]. Deficiency in SOCS1 and SOCS3 leads to activation of peripheral T cells, resulting in the development of inflammatory disease \[[@cit0033], [@cit0034]\]. STAT1 and STAT3, the major signal transducers pathways in which control the differentiation and development of Th1 and Th17, are negatively regulated by suppressor of cytokine signaling (SOCS) 1 and SOCS3 respectively \[[@cit0035]\].

![Overview of the role of Egr2 and Egr3 functions \[[@cit0032]\]](CEJI-42-30448-g002){#f0002}

Moreover, Egr2 regulate Batf, a transcriptional factor that regulates IL-17 expression and Th17 differentiation, by blocking it's binding to promoters of Th17 cytokines, thus contributing to prevent immunopathology in autoimmune disease \[[@cit0036]\].

Zhu *et al.* \[[@cit0037]\], showed that in Egr2 cKO, CD44^high^ T cells are hyperactive and hyperproliferative in vivo, which can lead to development of a late onset lupus-like autoimmune disease characterized by hair loss, skin lesions, severe glomerulonephritis, the accumulation of IFN-γ and IL-17 producing CD4+ T cells, significant infiltration of T cells into multiple organs and increased total serum Ig in comparison to age matched WT mice. So, this indicated intrinsic role of Egr2 not only in proliferation and inflammation of effector T cells but also in prevention of developing lupus-like autoimmune disease. CD44^high^ is a marker for memory and effector T cells \[[@cit0038]\]. Significant production of IL-17 and IFN-g is closely related to the pathogenesis of systemic lupus erythematosus \[[@cit0039]\]. Moreover, one study demonstrated that diminished expression of Egr2 and Egr3 was ameliorated by a peptide, hCDR1, treatment in SLE by downregulation of Akt phosphorylation in which led to down-regulated IL-2 mRNA expression and IFN-γ secretion. On the other hand, it was associated with increased expression of E3 ligase Cbl-b and immunosuppressive cytokine TGFβ, inducing anergy. So, it showed negative regulators Egr2 and Egr3 have indispensible role for the maintenance of SLE \[[@cit0040]\]. Akt is an important kinase that plays a key role in T cell survival, activation and proliferation and it provides costimulatory signals and can activated either by CD28 or following cross-linking of TCR \[[@cit0041]\].

Concluding remarks and perspectives {#sec6}
===================================

Egr transcription factors are involved in a vast array of functions, particularly their role in regulating of immune response has been investigated. Their role in the induction of differentiation of lymphocyte precursors, B and T cell activation, as well as their involvement in the anergy has been demonstrated.

Egr2 acts in many ways in a manner expected of a master regulator for cell proliferation and death, some having proliferative functions in specific contexts and others promoting growth arrest. These differences can be influenced by the cell types and signaling environment.

Moreover, Egr2 and 3 act as negative regulators of immune response, in specific by their effect in the peripheral tolerance mechanism such as anergy. Furthermore, Egr2 and 3 deficiency has been related to the development of autoimmune diseases in murine conditional Egr2 knock-out models.

Also, their role in apoptosis through FasL promoter has been addressed, however this has not been consistent and corroborated. Although TCR signaling seems to be the key elements for the expression of Egr transcriptional factors, little is known about the precise mechanism of Egr expression which needs to be elucidated.
